Maccura Biotechnology Co.Ltd (300463.SZ) Bundle
Who's buying Maccura Biotechnology Co.Ltd (300463.SZ) and why does a roughly ¥10 billion market cap now draw both major institutions and influential individuals? With Shenzhen Maccura Investment Co., Ltd. holding 25%, National Social Security Fund 8%, China Merchants Industry Holdings 5% and individual investor Wang Wei at 15%, the ownership mix signals concentrated strategic influence alongside retail confidence; yet the company's 2024 results-revenue of ¥2.55 billion (down 11.98%) and net income of ¥126.81 million (down 59.44%)-have clearly reshaped investor sentiment as the stock trades within a 52‑week range of ¥10.90-¥15.40 while analysts raised the average price target by 10.04% to ¥15.20, and Maccura's focused platforms in clinical biochemistry, chemiluminescent immunoassay, rapid diagnostics, thrombosis/hemostasis and molecular diagnosis plus its 2018 U.S. subsidiary and sustained R&D spending frame the trade‑offs driving different investor types to take positions now.
Maccura Biotechnology Co.Ltd (300463.SZ) - Who Invests in Maccura Biotechnology Co.Ltd and Why?
Maccura Biotechnology attracts a mix of strategic, institutional and retail investors driven by its in vitro diagnostics (IVD) franchise, R&D intensity and international expansion. Key ownership and appeal factors shape investor profiles and motives.- Major shareholders (indicative as of Oct 2023 / latest disclosed): Shenzhen Maccura Investment Co., Ltd. ~25% - strategic/insider holder
- National Social Security Fund ~8% - long-term institutional investor seeking defensive healthcare exposure
- China Merchants Industry Holdings Co., Ltd. ~5% - industrial/strategic investor
- Individual significant holder: Wang Wei ~15% - founder/insider alignment with company strategy
- Retail and other institutional holders - attracted by growth potential in diagnostics and R&D pipeline
- Product breadth across clinical biochemistry, chemiluminescent immunoassay, rapid diagnostics, thrombosis/hemostasis and molecular diagnostics
- R&D commitment with significant revenue reinvested into innovation, appealing to long-horizon investors
- International expansion (e.g., wholly‑owned U.S. subsidiary established in 2018) providing geographic diversification
- Valuation profile following market-cap and share-price volatility that can attract value or event-driven investors
- Strategic insider ownership providing governance alignment for long-term plans
| Metric | Value | Notes |
|---|---|---|
| Market capitalization (Oct 2023) | ¥10 billion (approx.) | Reflects mid-cap status on Shenzhen exchange |
| 2024 Revenue | ¥2.55 billion | Down 11.98% YoY |
| 2024 Net Income | ¥126.81 million | Down 59.44% YoY |
| 52-week share price range | ¥10.90 - ¥15.40 | Indicates recent volatility and investor sentiment shifts |
| Notable shareholders | Shenzhen Maccura ~25%, Wang Wei ~15%, NSS Fund ~8%, China Merchants ~5% | Mix of strategic, insider and institutional investors |
| International footprint | U.S. wholly‑owned subsidiary (est. 2018) | Supports export and regulatory strategy |
| R&D intensity | Significant portion of revenue | Supports product pipeline and competitiveness |
Maccura Biotechnology Co.Ltd (300463.SZ) Institutional Ownership and Major Shareholders of Maccura Biotechnology Co.Ltd
As of October 2023, the shareholder base of Maccura Biotechnology Co.Ltd (300463.SZ) combined concentrated institutional stakes with a notable individual holding, producing a mixed governance profile that influences strategy, R&D funding and market perceptions.
- Largest shareholder: Shenzhen Maccura Investment Co., Ltd. - 25% (strategic/controlling institutional investor).
- Major public institutional investor: National Social Security Fund - 8% (long-term, stabilizing investor).
- Strategic industrial investor: China Merchants Industry Holdings Co., Ltd. - 5% (industry-aligned institutional stake).
- Significant individual investor: Wang Wei - 15% (large personal holding with strong influence).
- Estimated remaining free float / other shareholders - 47% (liquidity and retail/institutional mix).
| Shareholder | Stake (%) | Type | Role / Impact |
|---|---|---|---|
| Shenzhen Maccura Investment Co., Ltd. | 25 | Institutional - Largest shareholder | Controls strategic direction, provides capital support for R&D and M&A decisions |
| National Social Security Fund | 8 | Institutional - Sovereign/DFI | Long-term investor signaling confidence; stabilizes share price during volatility |
| China Merchants Industry Holdings Co., Ltd. | 5 | Institutional - Industrial investor | Sector expertise and potential strategic partnership opportunities |
| Wang Wei (individual) | 15 | Individual investor | Significant personal stake that can influence governance and voting outcomes |
| Other shareholders / free float | 47 | Mixed (retail + smaller institutions) | Provides market liquidity and diverse investor sentiment |
| Aggregate institutional ownership (not exhaustive) | 38 | Institutional | Combined institutional stakes deliver governance stability and capital access |
- With 25% ownership, Shenzhen Maccura Investment is positioned to guide board appointments, R&D prioritization and capital allocation.
- The National Social Security Fund's 8% holding typically signals confidence to other long-term investors and can dampen sell-side pressure.
- China Merchants Industry's 5% stake underscores strategic industrial interest that may translate to collaboration on commercialization or supply-chain initiatives.
- Wang Wei's 15% individual stake represents concentrated private influence that can align or counterbalance institutional agendas.
Further context on company history, ownership structure and how Maccura operates can be found here: Maccura Biotechnology Co.Ltd: History, Ownership, Mission, How It Works & Makes Money
Maccura Biotechnology Co.Ltd (300463.SZ) Key Investors and Their Impact on Maccura Biotechnology Co.Ltd
Maccura Biotechnology's shareholder structure is concentrated among a few large holders whose combined stakes (25% + 15% + 8% + 5% = 53%) give them effective control over major strategic and governance decisions. The profile below outlines who the major investors are, their likely motivations, and the tangible impact they exert on corporate direction, capital allocation and market perception.- Shenzhen Maccura Investment Co., Ltd. - 25%: largest controlling shareholder; drives long-term strategy, board appointments, dividend policy and major M&A or CAPEX decisions.
- Individual investor Wang Wei - 15%: significant personal stake that can influence management culture, operational priorities and continuity; often aligns with founder/management interests.
- National Social Security Fund (NSSF) - 8%: signals institutional confidence and stability, improves access to other institutional capital and supports valuation multiples.
- China Merchants Industry Holdings Co., Ltd. - 5%: strategic corporate investor likely to pursue commercial partnerships, distribution synergies and industry collaborations.
| Investor | Stake (%) | Primary Influence | Potential Actions |
|---|---|---|---|
| Shenzhen Maccura Investment Co., Ltd. | 25 | Control & strategic direction | Board control, long-term strategy, capital allocation |
| Wang Wei (individual) | 15 | Founder-level influence / governance | Executive appointments, cultural continuity, strategic advocacy |
| National Social Security Fund | 8 | Institutional endorsement | Stability, attract institutional peers, reduce discount for lack of liquidity |
| China Merchants Industry Holdings Co., Ltd. | 5 | Strategic industrial partner | Commercial tie-ups, channel expansion, joint projects |
| Other public & retail holders | 47 | Liquidity & market pricing | Market discipline, short-term trading, governance oversight |
- Combined majority (53%) held by top four investors creates coordination potential - faster decision-making but also higher responsibility to minority shareholders.
- Presence of the National Social Security Fund reduces perceived governance risk and tends to support higher institutional ownership over time.
- Strategic corporate investor (China Merchants) increases likelihood of operational collaborations, potentially improving revenue diversification and margins.
- Large individual stake (Wang Wei) suggests alignment with management but raises the importance of robust independent director safeguards to protect minority interests.
- Shareholder expectations likely emphasize steady R&D investment, regulatory compliance, and protecting export/local market channels given biotech sector dynamics.
Maccura Biotechnology Co.Ltd (300463.SZ) - Market Impact and Investor Sentiment
In 2024 Maccura Biotechnology Co.Ltd reported revenue of ¥2.55 billion, down 11.98% year‑over‑year, while net income plunged 59.44% to ¥126.81 million. Those headline declines materially dented investor confidence and contributed to share‑price pressure through the year, even as the company maintains strategic initiatives intended to restore growth.- Revenue (2024): ¥2.55 billion (-11.98% YoY)
- Net income (2024): ¥126.81 million (-59.44% YoY)
- 52‑week stock price range: ¥10.90 - ¥15.40 (indicating elevated volatility)
- Analyst average price target: raised 10.04% to ¥15.20
- U.S. wholly‑owned subsidiary established: 2018 (sign of international expansion)
| Metric | Value | Notes |
|---|---|---|
| Revenue (2024) | ¥2.55 billion | Down 11.98% vs prior year |
| Net income (2024) | ¥126.81 million | Down 59.44% vs prior year |
| 52‑week range | ¥10.90 - ¥15.40 | Reflects market volatility and shifting sentiment |
| Analyst avg. price target | ¥15.20 | Up 10.04% - suggests cautiously constructive outlook |
| International footprint | U.S. subsidiary (2018) | Supports market access and revenue diversification |
- Buyers attracted by depressed valuation and upside to analyst targets (value/turnaround investors)
- Long‑term growth investors focused on R&D pipeline and international expansion
- Short‑term traders and momentum funds reacting to price volatility and news flow
- Institutional holders monitoring recovery signals (margins, revenue stabilization)
Maccura Biotechnology Co.Ltd (300463.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.